ABVC BioPharma, Inc.
ABVC
$1.28
$0.054.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -387.00% | -215.73% | -139.52% | 70.29% | -90.87% |
| Total Depreciation and Amortization | 274.98% | -9.77% | -29.31% | 11.12% | -134.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 335.55% | 312.42% | 272.77% | -90.18% | 550.07% |
| Change in Net Operating Assets | 76.65% | -348.74% | -309.81% | 94.30% | 35.49% |
| Cash from Operations | -102.11% | -321.43% | -322.99% | 43.52% | -63.09% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 59.87% | -2,942.41% | -32.74% | -- | 196.24% |
| Cash from Investing | 59.87% | -2,942.41% | -32.74% | -- | 196.24% |
| Total Debt Issued | 569.15% | 122.27% | -98.99% | -- | -241.33% |
| Total Debt Repaid | 38.59% | -87.44% | -- | -- | 5.09% |
| Issuance of Common Stock | 592.27% | 70.92% | 1,456.34% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 78.76% | -92.44% | 422.30% |
| Cash from Financing | 242.32% | 1,491.15% | 140.25% | -53.60% | 774.48% |
| Foreign Exchange rate Adjustments | 248.57% | 1,423.53% | -837.04% | 126.05% | 102.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 403.83% | -920.66% | 278.04% | -80.28% | 123.23% |